Latest Content

Pirtobrutinib significantly improved progression-free survival in treatment-naïve CLL compared with bendamustine plus rituximab.

Value-based care adoption in employer insurance requires replacing fragmented point solutions with unified, at-risk performance contracts that align vendors, providers, and members around total cost and quality goals.

Self-insured employers face regulatory challenges when adopting value-based contracts, requiring careful data governance, standardized metrics, and legal frameworks to align with federal value-based care models.

Employers struggle to define value from health care spending amid complexity and misaligned incentives. Achieving measurable outcomes requires transparency, incentive realignment, and gradual, employee-centered change.

A large review identifies 70 safety signals for bimekizumab, confirming known risks while revealing previously unreported adverse events.

Semaglutide, sotatercept, and bentracimab trials were attendees’ main focus at the American College of Cardiology 2025 Annual Scientific Session.

Artificial intelligence and lung cancer highlighted the top conference coverage from the Association of Cancer Care Centers Annual Meeting in Washington, DC.

Inebilizumab gains FDA approval for treating generalized myasthenia gravis, showing significant improvements in muscle strength and steroid reduction.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.